Showing 1741-1750 of 2094 results for "".
EHRs in 2013: What are you Willing to Live With?
https://practicaldermatology.com/topics/practice-management/ehrs-in-2013-what-are-you-willing-to-live-with/22910/Satisfaction with EHRs could be defined by what hinders your workflow the least.Currents: Acne & Rosacea
https://practicaldermatology.com/topics/acne-rosacea/currents-acne-rosacea/23514/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-6/23116/Currents: Where Are the Cosmetic Dermatology Patients?
https://practicaldermatology.com/topics/practice-management/currents-where-are-the-cosmetic-dermatology-patients/20518/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-10/23206/New Products and Pharmacological Developments
https://practicaldermatology.com/columns/new-products/new-products-and-pharmacological-developments/20449/A Practical Approach to Disorders of Hypopigmentation
https://practicaldermatology.com/topics/pigmentary-disorders/a-practical-approach-to-disorders-of-hypopigmentation/67254/Hypopigmentation comprises a broad spectrum of disorders characterized by decreased pigmentation in the presence of intact but functionally impaired melanocytes.Medical Education and Technology: Intertwined like the Rod of Asclepius
https://practicaldermatology.com/columns/clinical-focus-1/medical-education-and-technology-intertwined-like-the-rod-of-asclepius/23453/Natural Products that Exhibit Antifungal Activity
https://practicaldermatology.com/topics/general-topics/natural-products-that-exhibit-antifungal-activity/20360/Can natural products fight the fungus among us?Advanced Management Solutions for High-Grade Cutaneous Toxicities to Cancer Therapy
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advanced-management-solutions-for-high-grade-cutaneous-toxicities-to-cancer-therapy/57176/The emergence of immune checkpoint inhibitors (ICIs) has fundamentally altered the prognosis for patients with advanced skin malignancies, yet the high incidence of cutaneous immune-related adverse events (irAEs) remains a significant barrier to treatment continuity. Here, we review the clinical man